Dataset Information

Sheppard2018 - Toxic Activity of K1 Killer Yeast Protein

ABSTRACT: This is a deterministic model built using COPASI. It simulates the toxin activity of K1 toxin produced by Saccharomyces cerevisiae from inoculation through to toxin-induced cell death of a population of susceptible S.cerevisiae. The model can be used to track the kinetics of toxin action via either its primary action pathway seen at high concentrations or its secondary action pathway, via induced apoptosis, seen at low concentrations.

SUBMITTER: Sean Sheppard

PROVIDER: MODEL1804230001 | BioModels | 2019-03-21

REPOSITORIES: BioModels

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	MODEL1804230001?filename=Sheppard2018%20-%20Toxic%20Activity%20of%20K1%20Killer%20Yeast%20Protein.cps	Other
	MODEL1804230001?filename=Sheppard2018%20-%20Toxic%20Activity%20of%20K28%20Killer%20Yeast%20Protein.cps	Other

Items per page:

1 - 2 of 2

Publications

Dynamic modelling of the killing mechanism of action by virus-infected yeasts.

Sheppard Sean S Dikicioglu Duygu D

Journal of the Royal Society, Interface 20190301 152

Killer yeasts are microorganisms, which can produce and secrete proteinaceous toxins, a characteristic gained via infection by a virus. These toxins are able to kill sensitive cells of the same or a related species. From a biotechnological perspective, killer yeasts are beneficial due to their antifungal/antimicrobial activity, but also regarded as problematic for large-scale fermentation processes, whereby those yeasts would kill starter cultures species and lead to stuck fermentations. Here, w ...[more]

PMID: 30890050

Similar Datasets

Project description:Purpose: Deregulated phosphatidylinositol 3-kinase pathway signaling through AGC kinases including AKT, p70S6 kinase, PKA, SGK and Rho kinase, is a key driver of multiple cancers. The simultaneous inhibition of multiple AGC kinases may increase antitumor activity and minimize clinical resistance compared with a single pathway component. Experimental Design: We investigated the detailed pharmacology and antitumor activity of the novel clinical drug candidate AT13148, an oral ATP-competitive multi-AGC kinase inhibitor. Gene expression microarray studies were undertaken to characterize the molecular mechanisms of action of AT13148. Results: AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK and SGK substrate phosphorylation and induced apoptosis in a concentration and time-dependent manner in cancer cells with clinically relevant genetic defects in vitro and in vivo. Antitumor efficacy in HER2-positive, PIK3CA-mutant BT474 breast, PTEN-deficient PC3 human prostate cancer and PTEN-deficient MES-SA uterine tumor xenografts was demonstrated. We show for the first time that induction of AKT phosphorylation at serine 473 by AT13148, as reported for other ATP-competitive inhibitors of AKT, is not a therapeutically relevant reactivation step. Gene expression studies showed that AT13148 has a predominant effect on apoptosis genes, whereas the selective AKT inhibitor CCT128930 modulates cell cycle genes. Induction of upstream regulators including IRS2 and PIK3IP1 due to compensatory feedback loops was observed. Conclusions: The clinical candidate AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which demonstrates a distinct mechanism of action from other AKT inhibitors. AT13148 will now be assessed in a first-in-human Phase I trial. The PTEN-deficient U87MG glioblastoma cell line was treated for 6 hours with vehicle control (DMSO) or to different concentrations of AT13148 and CCT128930 (0.1uM, 1xGI50 and 3XGI50).